There is growing variety of treatment options for patients with myeloproliferative neoplasms (MPNs), sparking hope and better outcomes for patients with the disease, according to Dr. Marina Kremyanskaya, an assistant professor of medicine and medical oncology at the Mount Sinai Icahn School of Medicine in New York.
In an interview with CURE®, Kremyanskaya, who was also honored as one of the 2023 MPN Heroes, discussed the improved capability to give patients a better understanding of their diagnosis and disease pathology.
READ MORE:CURE Celebrates 8 Honorees at MPN Heroes Event
Additionally, there are numerous ongoing clinical trials — many of which were presented at the 2023 American Society of Hematology Annual Meeting — instilling hope and promising additional future options that are not yet known.
Transcript
We see a lot of different … options for patients, in terms of what treatment options are available and what we can tell them about their diagnosis, what we know about their diagnosis, about the pathology of the disease. And we can do a little bit better prediction of how things are going to go.
I think in general, we’re still talking about means and averages, which I think makes it difficult for an individual patient to understand that and to also sort of make their life decisions based on that. But we have a lot more treatment options. There is a huge clinical trial portfolio going on, which we will be hearing more at this at this meeting in the next few days. And so there are many more options for patients.
And so, and there’s a lot of hope and I think that it makes it easier to, to say to patients, “Well, hopefully things will go well on this treatment and then there will be other options in the future which we don’t even know about at this point.”
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
